Lung Cancer News and Research

Latest Lung Cancer News and Research

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom.

18 Dec 2009

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients.

18 Dec 2009

Study findings highlight the need to develop specific health policies to address social disparities

Racial and ethnic disparities in cancer survival are greatest for cancers that can be detected early and treated successfully, including breast and prostate cancer, according to a study by researchers at Columbia University's Mailman School of Public Health and Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center/NewYork-Presbyterian Hospital.

18 Dec 2009

Brachytherapy for lung cancer

A 58-year-old man who lives in Corona, Queens came to the emergency room of New York Hospital Queens (NYHQ) with extreme pain and tingling in his left arm. Although he did not realize it at the time, he had lung cancer. Recently, he made medical history as the first patient in the United States to be treated for lung cancer through the use of radioactive pellets placed directly in the tumor, and today his recovery is going well. Known as brachytherapy, this treatment approach is commonly used to treat prostate cancer.

18 Dec 2009

Phase 2 clinical study of STA-9090 in NSCLC initiated

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 2 clinical study of STA-9090 in non-small cell lung cancer (NSCLC).

18 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Applied Biosystems, part of Life Technologies Corporation, today announced the publication of a paper in the journal Nature that demonstrates the power of next-generation DNA sequencing used to identify DNA mutations in a small cell lung cancer (SCLC) line and identify the mutational burden associated with tobacco smoking.

17 Dec 2009

Typical smoker acquires one mutation for every 15 cigarettes and all cancers are caused by mutations

Research teams led by the Wellcome Trust Sanger Institute announce the first comprehensive analyses of cancer genomes.

17 Dec 2009

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

17 Dec 2009

Researchers discover new gene involved in lung cancer using DNA sequencing technology

Aided by next-generation DNA sequencing technology, an international team of researchers has gained insights into how more than 60 carcinogens associated with cigarette smoke bind to and chemically modify human DNA, ultimately leading to cancer-causing genetic mutations.

17 Dec 2009

Patients involved in Novelos Therapeutics' pivotal Phase III trial live longer than expected

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published an exclusive interview with the CEO of Novelos Therapeutics, Inc., Harry S. Palmin.

16 Dec 2009

Health experts discuss new treatment strategies for lung cancer at AACR-IASLC Joint Conference

In partnership with the International Association for the Study of Lung Cancer, the American Association for Cancer Research will host the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, which will bring together leaders from all over the world who share the goal of eradicating this form of cancer.

15 Dec 2009

Clarient and BioView team up to develop diagnostic tool for early detection of lung cancer

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, and BioView Ltd. (TASE: BIOV) today jointly announced that they will collaborate on studies to validate the clinical utility of a non-invasive test for the early detection of non-small cell lung cancer.

14 Dec 2009

Anti-estrogens may reduce the risk of death from lung cancer, according to study results

Anti-estrogens as therapy for breast cancer may also reduce the risk of death from lung cancer, according to study results presented at the CTRC-AACR San Antonio Breast Cancer Symposium, held here Dec. 9-13, 2009.

11 Dec 2009

HTDS comments on its recent stock price activity

Hard to Treat Diseases (HTDS) http://www.htdsmedical.com the company has been asked to comment on recent activity in its stock price. First, we would like our shareholders to be reassured and take comfort in the fact that there is no news that they do not know about. While there are several significant pending transactions they are not ready to be announced yet, however will be in due and appropriate time.

11 Dec 2009

Initiation of multi-national Phase III study of Stimuvax announced

Merck KGaA, Darmstadt, Germany, today announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC).

11 Dec 2009

Michigan goes smoke-free

The Michigan Legislature today delivered a historic victory for health and the public's right to breathe clean air by passing legislation to make almost all workplaces, including all restaurants and bars, smoke-free. Gov. Jennifer Granholm has said she will sign the bill, which will make Michigan the 27th state to pass a strong smoke-free law that includes all restaurants and bars.

10 Dec 2009

Biomoda, Christiana Care Health System partner in study of CyPath lung cancer diagnostic test

Cancer diagnostics company Biomoda, Inc. today announced that The Helen F. Graham Cancer Center associated with Christiana Care Health System, a screening site for the International Early Lung Cancer Program (I-ELCAP), will recruit a cohort of patients diagnosed with lung cancer to participate in the final stage of the Phase II pilot study of the investigational CyPath® assay, an early-stage diagnostic test for lung cancer.

10 Dec 2009

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

Oncothyreon Inc. today announced that Merck KGaA of Darmstadt, Germany, has initiated a Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The trial, named INSPIRE (Stimuvax trial In Asian NSCLC Patients: Stimulating Immune Response), is anticipated to enroll approximately 420 patients in China, Hong Kong, South Korea, Singapore and Taiwan.

10 Dec 2009

Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. today announced financial results for the second quarter of fiscal year (FY) 2010 ended October 31, 2009. Total revenue for the second quarter of FY 2010 increased 255% to $6,896,000, compared to $1,941,000 for the comparable prior year quarter.

10 Dec 2009

Lung Cancer News and Research

Latest Lung Cancer News and Research

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Study findings highlight the need to develop specific health policies to address social disparities

Brachytherapy for lung cancer

Phase 2 clinical study of STA-9090 in NSCLC initiated

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Typical smoker acquires one mutation for every 15 cigarettes and all cancers are caused by mutations

FDA Advisory Committee votes against the approval of Tarceva

Researchers discover new gene involved in lung cancer using DNA sequencing technology

Patients involved in Novelos Therapeutics' pivotal Phase III trial live longer than expected

Health experts discuss new treatment strategies for lung cancer at AACR-IASLC Joint Conference

Clarient and BioView team up to develop diagnostic tool for early detection of lung cancer

Anti-estrogens may reduce the risk of death from lung cancer, according to study results

HTDS comments on its recent stock price activity

Initiation of multi-national Phase III study of Stimuvax announced

Michigan goes smoke-free

Biomoda, Christiana Care Health System partner in study of CyPath lung cancer diagnostic test

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in